VivoSeq
Other

CLL/SLL

4

Pipeline Programs↗

7

Active Trials↗

8

Companies Involved↗

CLL/SLL is an early-stage landscape with 4 programs across 8 companies. The most active players are Sanofi, Ascentage Pharma Group Inc., Newave Pharmaceutical Inc.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.

0 programs

PreclinicalN

Newave Pharmaceutical Inc

0 programs

PreclinicalF

Fochon Pharmaceuticals, Ltd.

0 programs

PreclinicalS

Shengke Pharmaceuticals Pty Ltd

0 programs

PreclinicalD

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 14

SYNCAR-001

Synthekine

STK-009

Synthekine

Cyclophosphamide

Baxter Healthcare Corporation

Fludarabine

Sanofi

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

16

clinical trials

Completed4 · 25%
Recruiting4 · 25%
Terminated3 · 19%
Active, not recruiting2 · 13%
Not yet recruiting1 · 6%
Withdrawn1 · 6%
Other1 · 6%

Clinical Trials

Trial Activity

16 trials

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Recruiting·—·Phase 2·NCT07014917·62 enrolled
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 1·NCT04215809·144 enrolled
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Recruiting·DDizal (Jiangsu) Pharmaceutical Co., Ltd.·Phase 3·NCT07139873·250 enrolled
Global Trial in APG2575 for Patients With CLL/SLL
Recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 3·NCT06104566·400 enrolled
A Study of FCN-338 in Patients With Chronic CLL/SLL
Active, not recruiting·FFochon Pharmaceuticals, Ltd.·Phase 1·NCT04682808·99 enrolled
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies
Active, not recruiting·SSynthekine·Phase 1·NCT05665062·36 enrolled
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Not yet recruiting·NNewave Pharmaceutical Inc·Phase 3·NCT07342478·306 enrolled
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Completed·—·Phase 2·NCT02135133·27 enrolled
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
Completed·SSecuraBio·Phase 3·NCT02049515·99 enrolled
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Completed·Eli Lilly logoEli Lilly·Phase 1/2·NCT03740529·803 enrolled
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Completed·PPrecision BioSciences, Inc.·Phase 1/2·NCT04030195·18 enrolled
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
Terminated·SShengke Pharmaceuticals Pty Ltd·Phase 1·NCT04840784·9 enrolled
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Terminated·—·Phase 1·NCT00543114·9 enrolled
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
Terminated·SSecuraBio·Phase 1·NCT02292225·3 enrolled
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Withdrawn·HHutchmed·Phase 1·NCT05176691
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)